Towards a sustainable system of drug development
Files
Publication date
2014-11-01
Authors
Moors, Ellen
Cohen, Adam F.
Schellekens, Huub
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
Abstract
Drug development has become the exclusive activity of large pharmaceutical companies. However, the output of new drugs has been decreasing for the past decade and the prices of new drugs have risen steadily, leading to access problems for many patients. By analyzing the history of drug development and the pharmaceutical industry, we identified the main factors causing this system failure. Although many solutions have been suggested to fix the drug development system, we believe that a combination of reforms of the regulatory and patent systems is necessary to make drug development sustainable. These reforms must be combined with a larger, open-access role for public research institutes in the discovery, clinical evaluation and safety evaluation of new drugs.
Keywords
generic drug, new drug, cost effectiveness analysis, drug approval, drug development, drug industry, drug manufacture, drug marketing, drug safety, drug screening, drug surveillance program, human, industrial production, mergers and acquisitions, patent, public-private partnership, reimbursement, review, Taverne
Citation
Moors, E H M, Cohen, A F & Schellekens, H 2014, 'Towards a sustainable system of drug development', Drug Discovery Today, vol. 19, no. 11, pp. 1711-1720. https://doi.org/10.1016/j.drudis.2014.03.004